SCHEMBL30772148

SCHEMBL30772148

Cc1cccc(-c2csc(NC(=O)CCN3CCN(Cc4ccccc4)CC3)n2)c1

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.82
MMP8 P22894 1/20 0.82
MYD88 Q99836 1/20 0.59
ALK Q9UM73 6/20 0.57
HRH1 P35367 1/20 0.56
MAPT P10636 2/20 0.54
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.54
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ACHE P22303 1/20 0.53
TSHR P16473 1/20 0.53
ELOVL1 Q9BW60 1/20 0.51
NPC1 O15118 1/20 0.51
POLB P06746 1/20 0.50
PARP1 P09874 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24993420 1.00 MMP2 (0.82) MMP2MMP8MYD88ALKHRH1
SCHEMBL30989359 0.91 MMP2 (0.66) MMP2MMP8ALKMAPTALDH1A1
SCHEMBL15401374 0.90 MMP2 (1.00) MMP2MMP8MYD88HRH1MAPT
SCHEMBL30772150 0.90 MMP2 (0.86) MMP2MMP8MYD88HRH1MAPT
Hydrochloric Acid SCHEMBL31496761 0.89 MMP2 (0.98) MMP2MMP8MYD88HRH1MAPT
SCHEMBL30173490 0.88 MMP2 (0.78) MMP2MMP8MYD88ALKMAPT
SCHEMBL27235580 0.88 MMP2 (0.78) MMP2MMP8MYD88ALKMAPT
SCHEMBL27821015 0.83 MMP2 (0.82) MMP2MMP8MYD88ALKHRH1
SCHEMBL24993421 0.80 MMP2 (0.80) MMP2MMP8MAPTALDH1A1KDM4E
SCHEMBL30772149 0.76 ACHE (0.66) MMP2MMP8MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180898-A1 USE OF AMINOTHIAZOLE DERIVATIVE IN TREATMENT OF IMMUNE INFLAMMATION INNAMUNE PHARMACEUTICAL CO. LTD. (CN) 2024-06-06 US claimed
WO-2024027807-A1 USE OF AMINOTHIAZOLE DERIVATIVE IN PREPARING DRUG FOR IMMUNOLOGICAL INFLAMMATION 宁波亿诺药业有限公司 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180898-A1 USE OF AMINOTHIAZOLE DERIVATIVE IN TREATMENT OF IMMUNE INFLAMMATION AADAT, IDO1, IDO2 MMP2 2870/4885MMP8 1107/4885MYD88 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.